Alternate-day oral therapy with Nalfurafine hydrochloride as refractory pruritus for liver cirrhotic patients

Not Applicable

• Conditions: iver cirrhosis

• Registration Number: JPRN-UMIN000023638
• Lead Sponsor: Juntendo University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-08-16
• Study Completion: 2022-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Not provided

Exclusion Criteria

Patients who are regarded as inappropriate to participate the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess the rate of accomplish of alternate-day oral therapy with Nalfurafine hydrochloride

Secondary Outcome Measures

Name	Time	Method
1)To determine the plasma concentration of Nalfurafine hydrochloride during alternate-day oral therapy 2)To investigate the therapeutic effect according to gene polyrmorphism of OPRM1.